Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarker Discovery for Metabolic Dysfunction-associated Steatotic Liver Disease Utilizing Mendelian Randomization, Machine Learning, and External Validation

16 Jul 2025

Abstract excerpt

Background and Aims: The causal biomarkers for metabolic dysfunction-associated steatotic liver disease (MASLD) and their clinical value remain unclear. In this study, we aimed to identify biomarkers for MASLD and evaluate their diagnostic and prognostic significance. Methods: We conducted a Mendelian randomization analysis to assess the causal effects of 2,925 molecular biomarkers (from proteomics data) and 35...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Liver Disease and Transplantation
Share to Liver Disease Diagnosis and Treatment
Share to Liver Diseases and Immunity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40951528
DOI: 10.14218/jcth.2025.00270

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarker Discovery for Metabolic Dysfunction-associated Steatotic Liver Disease Utilizing Mendelian Randomization, Machine Learning, and External ValidationPMID 40951528Read ↗

Causal association of cholesterol metabolism-related proteins with hepatocellular carcinoma and dysfunction-associated steatotic liver disease: a mendelian randomization studySemantic proximity Read ↗

Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targetsSemantic proximity Read ↗

Causal relationship between key genes and metabolic dysfunction‐associated fatty liver disease risk mediated by immune cells: A Mendelian randomization and mediation analysisSemantic proximity Read ↗

Genetically predicted metabolites mediate the association between immune cells and metabolic dysfunction-associated steatotic liver disease: a mendelian randomization study.Semantic proximity Read ↗

Identifying disease progression biomarkers in metabolic associated steatotic liver disease (MASLD) through weighted gene co-expression network analysis and machine learningSemantic proximity Read ↗

Causal relationships between three plasma proteins and non-alcoholic fatty liver disease, mediated by Epstein-Barr virus EA-D antibody levels: a mendelian randomization study.Semantic proximity Read ↗

The Mediating Effect of 3-Methoxytyrosine on TWEAK Levels and Primary Sclerosing Cholangitis: A Genetic PerspectiveSemantic proximity Read ↗

UK Biobank-Based Genetic and Proteomic Network Insights into Metabolic Dysfunction-Associated Steatotic Liver Disease Pathogenesis.Semantic proximity Read ↗

An integrated proteogenomic investigation of the human liver uncovers molecular drivers of steatotic liver diseaseSemantic proximity Read ↗

High salt diet causally increases metabolic dysfunction-associated steatotic liver disease risk: A bidirectional mendelian randomization study.Semantic proximity Read ↗

Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction-Associated Steatotic Liver Diseases: A Pathway to Precision Medicine.Semantic proximity Read ↗

Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLDSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.